CD19 and neoplasm: Notably, our investigations revealed that CD19-targeted DASH CAR-T, with its distinctive secretory profile, exhibited superior expansion capability, higher ratios of naive and memory T cells, and enhanced anti-tumor activity compared to conventionally manufactured CAR-T cells.